Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Bladder Cancer
•
Medical Oncology
Would you add pembrolizumab to enfortumab to further treat a patient with metastatic bladder cancer that progressed on avelumab maintenance after cis/gem?
Related Questions
Would you recommend patients with newly diagnosed bladder cancer to discontinue SGLT2 inhibitors?
For patients with modest hyperbilirubinemia (Tbili 2-3) due to chronic liver disease, but otherwise normal liver indices, would you consider still utilizing enfortumab vedotin for metastatic urothelial carcinoma?
Based on NIAGARA data, do you now feel more comfortable offering cisplatin based chemotherapy to patients with impaired renal function?
Are you dose reducing/omitting IV dexamethasone as a pre-medication for anti-emesis in patients with MIBC when using durvalumab/gemcitabine/cisplatin?
How do you interpret NIAGARA efficacy given that adjuvant nivolumab was not administered in the comparator arm?
In patients with muscle-invasive bladder cancer seeking bladder preservation, would positive ctDNA affect your approach to trimodality therapy?
For neoadjuvant treatment of muscle invasive bladder cancer, are you utilizing durvalumab plus gemcitabine cisplatin over dose dense or accelerated MVAC?
Do you plan to extrapolate from the NIAGARA trial regarding peri-operative durvalumab/cis/gem to treat upper tract urothelial carcinoma?
How would do manage stage II/III Muscle invasive bladder cancer with large cell neuroendocrine histology?
How do you manage enfortumab vedotin related DKA that is refractory to standard therapy (insulin, fluids, etc)?
